Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stake Lessened by Portolan Capital Management LLC

Portolan Capital Management LLC lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 60.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 131,123 shares of the company's stock after selling 196,641 shares during the period. Portolan Capital Management LLC owned 0.27% of Amphastar Pharmaceuticals worth $4,869,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in AMPH. Smartleaf Asset Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after buying an additional 493 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares during the last quarter. Huntington National Bank grew its stake in shares of Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after purchasing an additional 361 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after buying an additional 388 shares during the last quarter. Finally, KBC Group NV lifted its stake in Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after purchasing an additional 650 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on AMPH. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH traded up $0.36 during midday trading on Friday, reaching $23.35. 735,039 shares of the company were exchanged, compared to its average volume of 462,779. The stock has a fifty day simple moving average of $27.78 and a 200 day simple moving average of $37.36. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.11 billion, a P/E ratio of 7.78, a PEG ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.64 and a 1 year high of $53.96.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.